Designated SMPs as enclosed

Net loss reportedResults restatedExceptional itemEmphasis of matterResults View source PDF Explain this filing

AARTIPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.1%Reaction day

₹732.10

prior close

₹706.80

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.7%-5.8% vs market

Pharmaceuticals peers, median of 165sector+0.2%-5.3% vs sector

On the reaction day the stock moved 5.8 pts less than Nifty Microcap 250 and 5.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

+0.0

15m

+0.6

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.1+0.7-5.8+0.2-5.3

Next day

-10.5+0.7-11.2-0.1-10.4

-11.6+0.0-11.7-0.3-11.3

-12.4-1.1-11.3-1.3-11.0

-13.1+0.0-13.1-1.2-11.9

-15.0+0.3-15.3-1.5-13.5

-14.0+1.1-15.1-0.6-13.4

15d

-11.8+4.9-16.6-0.3-11.5

-7.3+5.3-12.7+3.1-10.4

-6.7+6.9-13.6+4.1-10.8

+14.6+11.9+2.7+7.1+7.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Pharmalabs reported FY26 standalone revenue of Rs 1,797.55 crore, nearly flat versus FY25's Rs 1,771.35 crore. However, profit before tax declined sharply to Rs 234.24 crore from Rs 336.34 crore (~30% fall), and net profit fell to Rs 176.20 crore from Rs 257.35 crore (~32% decline). EPS dropped to Rs 19.44 from Rs 28.39. The company recognized a Rs 29.75 crore exceptional charge for new labour code provisions and a Rs 29.73 crore fair value loss on a foreign exchange derivative contract that was omitted from prior periods' calculations. Q3 FY26 figures were restated to reflect this correction. Consolidated revenue declined to Rs 1,819.44 crore from Rs 2,115.07 crore, partly due to Ganesh Polychem becoming a joint venture from April 2025 making numbers non-comparable. Board declared Rs 2 per share (40%) final dividend and appointed two senior management personnel. Auditors issued unmodified opinion with emphasis of matter on the derivative restatement.

Likely market impact

Significant profit decline and accounting restatement may create near-term volatility despite dividend declaration. The derivative omission from prior periods raises concerns about internal controls, though the impact is now fully recognized and audited.